Head-to-head evidence
Divalproex sodium (Depakote) vs valproate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABAergic neurotransmission · full Epilepsy pipeline
Divalproex sodium (Depakote)
Marketed by AbbVie
NCT00102713 · Phase 3 · completed
The study treated 50 children in a non-randomized, unblinded, single-arm design with no placebo or active comparator. Its primary clinical endpoint was partial seizure rate at Week 4, but no results are posted, so whether the endpoint was met cannot be assessed.
valproate
Marketed by AbbVie and partners
NCT00004817 · Phase 3 · completed
The study was described as a double-blind, active-controlled trial comparing valproate sodium with phenytoin in 385 participants, but the registry does not explicitly document randomization. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Divalproex sodium (Depakote)'s landscape · valproate's landscape